Consider a SGLT‐2 inhibitor if patient has established cardiovascular disease, chronic kidney disease, or heart failure; insulin dose may need to be reduced to prevent hypoglycaemia2. The gene discussed is SLC5A2; the disease is cardiovascular disorder.